Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.84 USD
-0.08 (-4.17%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.84 0.00 (0.00%) 5:44 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -154.15 | -213.91 | -164.83 | -102.99 | -101.66 |
Depreciation/Amortization & Depletion | 11.11 | 11.42 | 10.71 | 10.95 | 7.98 |
Net Change from Assets/Liabilities | -12.52 | -0.72 | 36.37 | -4.78 | -4.84 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.34 | 23.81 | 1.21 | 13.14 | 3.57 |
Net Cash From Operating Activities | -128.23 | -179.40 | -116.54 | -83.68 | -94.96 |
Property & Equipment | 2.90 | -2.93 | -15.95 | -5.96 | -7.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -20.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 17.60 |
Other Investing Activities | -5.01 | 0.00 | 56.46 | -1.20 | 9.49 |
Net Cash from Investing Activities | -2.10 | -22.93 | 40.51 | -7.16 | 20.10 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 25.25 | 8.07 | 26.65 | 152.87 | 93.15 |
Issuance (Repayment) of Debt | -35.85 | 47.11 | -10.55 | -18.22 | 0.00 |
Increase (Decrease) Short-Term Debt | -2.95 | 2.14 | 0.81 | -15.75 | 15.00 |
Payment of Dividends & Other Distributions | -8.77 | -8.78 | -8.78 | -6.75 | -2.56 |
Other Financing Activities | 55.05 | 26.79 | 140.86 | 60.26 | 41.12 |
Net Cash from Financing Activities | 32.74 | 75.32 | 148.99 | 172.41 | 146.71 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -97.59 | -127.01 | 72.97 | 81.56 | 71.85 |
Cash at Beginning of Period | 180.95 | 307.96 | 235.00 | 153.43 | 81.58 |
Cash at End of Period | 83.37 | 180.95 | 307.96 | 235.00 | 153.43 |
Diluted Net EPS | -8.47 | -14.54 | -11.84 | -9.75 | -10.94 |
Fiscal Year End for Fortress Biotech, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -67.85 | -39.02 | -154.15 | -125.17 | -114.45 |
Depreciation/Amortization & Depletion | 5.64 | 2.33 | 11.11 | 8.89 | 6.53 |
Net Change from Assets/Liabilities | 2.47 | 5.66 | -12.52 | 5.63 | 13.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 12.51 | 5.64 | 27.34 | 17.36 | 17.51 |
Net Cash From Operating Activities | -47.23 | -25.39 | -128.23 | -93.29 | -76.51 |
Property & Equipment | 0.00 | 0.00 | 2.90 | 2.97 | -2.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | -5.01 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -5.01 | -5.01 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | -2.10 | -2.04 | -7.04 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 39.71 | 14.88 | 25.25 | 14.30 | 39.82 |
Issuance (Repayment) of Debt | 5.00 | 0.00 | -35.85 | -22.47 | -12.47 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | -2.95 | -30.95 | -30.95 |
Payment of Dividends & Other Distributions | -4.37 | -2.18 | -8.77 | -6.58 | -4.39 |
Other Financing Activities | 1.78 | 15.16 | 55.05 | 34.81 | -0.21 |
Net Cash from Financing Activities | 42.12 | 27.86 | 32.74 | -10.88 | -8.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -5.10 | 2.47 | -97.59 | -106.21 | -91.74 |
Cash at Beginning of Period | 83.37 | 83.37 | 180.95 | 180.95 | 180.95 |
Cash at End of Period | 78.26 | 85.84 | 83.37 | 74.75 | 89.21 |
Diluted Net EPS | -0.73 | -1.03 | -0.78 | -0.94 | -3.60 |